Valeant And Progenics Announce U.S. Commercial Launch Of Relistor Tablet

(RTTNews) - Valeant Pharmaceuticals International, Inc. (VRX, VRX.TO) and Progenics Pharmaceuticals Inc. (PGNX) announced the U.S. commercial launch of RELISTOR (methylnaltrexone bromide) Tablets, which is now available for prescribing. RELISTOR Tablets (450 mg once daily) were approved by the U.S. Food and Drug Administration for the treatment of opioid-induced constipation or OIC in adults with chronic non-cancer pain on July 19, 2016.

RELISTOR (methylnaltrexone bromide) Tablets are contraindicated in patients with known or suspected gastrointestinal obstruction and patients at increased risk of recurrent obstruction, due to the potential for gastrointestinal perforation.

If severe or persistent diarrhea occurs during treatment, advise patients to discontinue therapy with RELISTOR and consult their healthcare provider, the company said.

Symptoms consistent with opioid withdrawal, including hyperhidrosis, chills, diarrhea, abdominal pain, anxiety, and yawning have occurred in patients treated with RELISTOR.